A Novel In Vivo Method Using Caenorhabditis elegans to Evaluate α-Glucosidase Inhibition by Natural Products for Type 2 Diabetes Treatment
A novel, simple and reliable method has been developed to directly determine pharmacological activities in an in vivo model of wild-type <i>C. elegans</i>. This allows the hypoglycemic activity to be directly attributed to in vivo treatment without quantifying phenotypic changes in mutant strains that may arise from other effects, opening the door to a simple analysis of in vivo pharmacological activities.
Authors
- Rita Yolanda Cavero (ORCID: https://orcid.org/0000-0002-8106-3243)
- J.L. Vizmanos (ORCID: https://orcid.org/0000-0001-7416-3679)
- María Pilar de Torre (ORCID: https://orcid.org/0000-0002-1112-344X)
- María Isabel Calvo (ORCID: https://orcid.org/0000-0002-3159-0336)
Institutions
- Navarre Institute of Health Research (ES)
- Instituto de Investigación Biosanitaria de Granada (ES)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3390/ph17121685
- Primary Topic
- Genetics, Aging, and Longevity in Model Organisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universidad de Navarra